Disclosed herein are fused bicyclic 2,4-diaminopyrimidine derivatives of formula I, wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful as Anaplastic Lymphoma Kinase (ALK) and c-MET inhibitors and as such are useful in the treatment of proliferative disorders such as colon cancer, breast cancer, renal cancer, lung cancer, hemangioma, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, squamous cell carcinoma, myeloid leukaemia, melanoma, glioblastoma and astrocytoma.
